DR. Reddy S Laboratories

Dr. Reddy S Laboratories (DRREDDY) is a large-cap Healthcare company valued at ₹1.03 lakh crore operating in Pharmaceuticals on the NSE and BSE.

Recent price move

Dr. Reddy S Laboratories last traded at ₹1,233, modestly up 1.17% on the day.

Recent developments

On 2026-08-04, the company launched Sugammadex injection in the US, expanding its presence in the global market. On 2026-07-22, the company reported a 69% decline in Q1 net profit to ₹434 crore, citing lower lenalidomide revenues and an unexpected setback related to semaglutide API. On 2026-06-24, the company experienced an 86% YoY plunge in Q4 net profit.

Financial performance

The company's annual revenue grew 3.2% to ₹33,700 crore, but net profit fell 27.4% to ₹4,158 crore. The latest quarter saw revenue drop 5.5% and net profit plunge 69.1%, reflecting a sharp decline in profitability compared to the same quarter a year earlier.

Valuation multiples

The stock trades at 24.5 times earnings, a discount to the Healthcare median of 32.0, 2.50 times book value. It yields 0.7%.

Things to watch

The company's net profit margin narrowed 5.2 percentage points to 12.3%. The latest quarter net profit dropped 69.1%, and the stock is 15.4% below its 52-week high. The company also reported a significant decline in Q1 net profit, which may signal ongoing challenges in its core business.

Where it stands

Dr. Reddy's Laboratories reported a sharp decline in quarterly net profit, with a 69.1% drop to ₹436 crore, while annual net profit fell 27.4% to ₹4,158 crore. The stock is 15.4% below its 52-week high, and the net profit margin has narrowed significantly. The company's recent performance highlights challenges in maintaining profitability.

Summarised by DocStoX's model on 2026-10-10 from company filings, exchange data and news. This is a factual summary, not a rating or a recommendation. Informational only, not investment advice. Consult a SEBI-registered adviser before investing.